Ghosh, N., Chavez, J., Bastos-Oreiro, M., Diefenbach, C., Lossos, I. S., Shah, N., Assouline, S., Olszewski, A., Naik, S., Pham, S., Wei, M. C., Batlevi, C. L., To, I., Ead, W. S., Makadia, S., Peneul, E., Budde, E. (2025). Long-term follow-up with sustained progression-free survival (PFS) benefit after subcutaneous (SC) mosunetuzumab in combination with polatuzumab vedotin compared with rituximab plus polatuzumab vedotin in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma. Blood. https://doi.org/10.1182/blood-2025-1020